The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Biogen in a research note ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Biogen in a research note ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

The global compounding pharmacy market size is calculated at USD 14.58 billion in 2025 and is expected to reach around USD 22 ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

Smith and Winter’s work on a technique known as phage display was notably used to develop Humira (adalimumab), first approved in 2002 and now used in a range of inflammatory diseases.